1-Ethyl-8-hydroxy-3-[(1-methyl-1,2-dihydro-1'H-spiro[indole-3,4'-piperidin]-1'-yl)methyl]-3,4-dihydroquinolin-2(1H)-one | 574741-11-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 1-Ethyl-8-hydroxy-3-[(1-methyl-1,2-dihydro-1'H-spiro[indole-3,4'-piperidin]-1'-yl)methyl]-3,4-dihydroquinolin-2(1H)-one
• 英文别名: 1-ethyl-8-hydroxy-3-[(1-methylspiro[2H-indole-3,4'-piperidine]-1'-yl)methyl]-3,4-dihydroquinolin-2-one
• CAS: 574741-11-0
• 化学式: C₂₅H₃₁N₃O₂
• 分子量: 405.54
• InChiKey: IUQRWIFNMSBLEW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  30
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  47
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• N-substituted spiropiperidine compounds as ligands for ORL-1 receptor
  申请人：——

  公开号：US20030158219A1

  公开（公告）日：2003-08-21

  A compound of the formula: 1 or a pharmaceutically acceptable salt, ester or ether thereof, wherein R 1 through R 12 are independently hydrogen or the like; X 1 and X 2 are independently CH 2 or the like; R 13 is hydrogen or the like; or R 12 and R 13 taken together with three ring atoms of the quinoline ring separating said substituents form a heterocyclic ring; R 14 and R 15 are hydrogen or the like or these groups taken together form oxo; and the dotted line represents a single or double bond. These compounds are ligands for ORL-1 receptor and especially are antagonists for said receptor.

  该化合物的结构式为：1或其药用可接受的盐、酯或醚，其中R1到R12独立地是氢或类似物；X1和X2独立地是CH2或类似物；R13是氢或类似物；或者R12和R13与喹啉环的三个环原子一起形成杂环环；R14和R15是氢或类似物，或这些基团一起形成氧化物；虚线代表单键或双键。这些化合物是ORL-1受体的配体，特别是该受体的拮抗剂。
• N-SUBSTITUTED SPIROPIPERIDINE COMPOUNDS AS LIGANDS FOR ORL-1 RECEPTOR
  申请人：PFIZER INC.

  公开号：EP1470126A1

  公开（公告）日：2004-10-27
• US6869960B2
  申请人：——

  公开号：US6869960B2

  公开（公告）日：2005-03-22
• [EN] N-SUBSTITUTED SPIROPIPERIDINE COMPOUNDS AS LIGANDS FOR ORL-1 RECEPTOR<br/>[FR] COMPOSES SPIROPIPERIDINE N-SUBSTITUES UTILISES COMME LIGANDS POUR LE RECEPTEUR DE ORL-1
  申请人：PFIZER PHARMA

  公开号：WO2003064425A1

  公开（公告）日：2003-08-07

  A compound of formula (I) or a pharmaceutically acceptable salt, ester or ether thereof, wherein R1 through R12 are independently hydrogen or the like; X?1 and X2¿ are independently CH¿2? or the like; R?13¿ is hydrogen or the like; or R?12 and R13¿ taken together with three ring atoms of the quinoline ring separating said substituents form a heterocyclic ring; R?14 and R15¿ are hydrogen or the like or these groups taken together form oxo; and the dotted line represents a single or double bond. These compounds are ligands for ORL-1 receptor and especially are antagonists for said receptor.